Inhibitors of parg
Assignee858 Therapeutics, Inc.
InventorsShyama HERATH, James M. VEAL, Jeffrey A. STAFFORD, Taylor ALEXANDER, Grant SEILER, Riley MILLS, Christopher MCBRIDE, Donald S. KARANEWSKY
Life of this patent
Estimating the term…
Abstract
Provided herein are inhibitors of PARG, pharmaceutical compositions comprising the inhibitory compounds, and methods for using the PARG inhibitory compounds for the treatment of disease.
Claims70
A compound, or a pharmaceutically acceptable salt, stereoisomer, or deuteroisotope thereof, having the structure of Formula (I):
- wherein,
- B is a bond, C═O, or CN—OR9;
- W is a bond, —O—, or C(R10)(R11), or NR7;
- X is —S—, or —*Y═C(A)—;
- wherein the * indicates point of attachment to C—SO2 group;
- Y is N, C—H, C—F, C—O(optionally substituted C1-C6 alkyl), C—NH2, C—NH(optionally substituted C1-C6 alkyl), C—N(optionally substituted C1-C6 alkyl)2, C—SH, C—S(optionally substituted C1-C6 alkyl), C—NH(optionally substituted (heteroaryl)alkylene), —C—NH(optionally substituted (heteroaryl)alkynylene);
- A is selected from the group consisting of hydrogen, halo, —OH, —CN, optionally substituted C1-C6 alkoxy, —N(R7)2, optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally substituted C3-C7 carbocyclyl, optionally substituted (carbocyclyl)alkylene, optionally substituted (carbocyclyl)alkynylene, optionally substituted heterocyclyl, optionally substituted (heterocyclyl)alkylene, optionally substituted heteroaryl, and optionally substituted aryl;
- R1 is selected from the group consisting of optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted (cycloalkyl)alkylene, optionally substituted (aryl)alkylene, optionally substituted (heterocyclyl)alkylene, optionally substituted (heteroaryl)alkylene, optionally substituted (heteroaryl)alkynylene, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted C3-C7 carbocyclyl, and optionally substituted heterocyclyl;
- R2 and R3 are independently selected from the group consisting of hydrogen, halo, —OH, —CN, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted heterocyclyl, optionally substituted (cycloalkyl)alkylene, optionally substituted (heterocyclyl)alkylene, optionally substituted (aryl)alkylene, optionally substituted (heteroaryl)alkylene, optionally substituted (cycloalkyl)alkenylene, optionally substituted (heterocyclyl)alkenylene, optionally substituted (aryl)alkenylene, optionally substituted (heteroaryl)alkenylene, optionally substituted (cycloalkyl)alkynylene, optionally substituted (heterocyclyl)alkynylene, optionally substituted (heteroaryl)alkynylene, optionally substituted (aryl)alkynylene, optionally substituted (cycloalkyl)-O-alkylene, optionally substituted (heterocyclyl)-O-alkylene, optionally substituted (aryl)-O-alkylene, optionally substituted (heteroaryl)-O-alkylene, optionally substituted (cycloalkyl)-NR7-alkylene, optionally substituted (heterocyclyl)-NR7-alkylene, optionally substituted (aryl)-NR7-alkylene, optionally substituted (heteroaryl)-NR7-alkylene, optionally substituted (alkyl)-O-alkylene, optionally substituted (alkyl)-NR7-alkylene, optionally substituted (alkyl)-O-alkynylene, and optionally substituted (alkyl)-NR7-alkynylene;
- or
- optionally, R2 and R3 combine to form an optionally substituted carbocyclic or heterocyclic ring;
- R4, R5, R10, and R11 are independently selected from the group consisting of hydrogen, halo, —OH, —CN, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted (cycloalkyl)alkylene, optionally substituted (cycloalkyl)alkynylene, optionally substituted heterocyclyl, optionally substituted (heterocyclyl)alkylene, optionally substituted heteroaryl, and optionally substituted aryl;
- or optionally, R4 and R5 combine to form an optionally substituted carbocyclic or heterocyclic ring;
- or optionally, R3 and R4 combine to form an optionally substituted carbocyclic or heterocyclic ring;
- R6 is optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heterocyclyl, or an optionally substituted 1,1′-bi(cyclopropan)-1-yl;
- each R7 is independently hydrogen or an optionally substituted C1-C6 alkyl;
- and
- each R9 is independently hydrogen or an optionally substituted C1-C6 alkyl.
A compound, or a pharmaceutically acceptable salt, stereoisomer, or deuteroisotope thereof, described in Table 1.
A compound, or a pharmaceutically acceptable salt, stereoisomer, or deuteroisotope thereof, as described in Table 2.
Dependencies are inferred from the claim text.